Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Tuesday 29 September, 2020

Sensyne Health PLC

Holding(s) in Company

RNS Number : 4367A
Sensyne Health PLC
29 September 2020
 

Holding(s) in Company

 

Oxford, U.K. 29 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, notes that on 5 June 2020, Acacia Research Corporation (Nasdaq: ACTG) announced that it had entered into an agreement with Link Fund Solutions Limited ("LFS") to purchase shares in a number of public and private life sciences companies from the LF Equity Income Fund which was previously managed by Woodford Investment Management Limited. 

The agreement was structured to take ownership of portfolio positions in a staged manner. Sensyne Health welcomes Acacia Research as an 11.8% shareholder and the clarity brought to the market with this announcement for the previously anticipated share transfer.

Clifford Press, CEO of Acacia Research , commented:

" We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth."

 

TR-1: Standard form for notification of major holdings


NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Sensyne Health Plc

 

Schrödinger Building

Heatley Road

Oxford Science Park

Oxford OX4 4GE

United Kingdom

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify):


3. Details of person subject to the notification obligation

Name

Acacia Research Corporation

City and country of registered office (if applicable)

Irvine, California, United States of America

4. Full name of shareholder(s)  (if different from 3)

Name

Merton Acquisition HoldCo LLC

City and country of registered office (if applicable)

Irvine, California, United States of America

5. Date on which the threshold was crossed or reached:

28/09/2020

6. Date on which issuer notified (DD/MM/YYYY):

28/09/2020

7. Total positions of person(s) subject to the notification obligation:


% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

11.8%


11.8%

128,571,514

Position of previous notification (if applicable)





 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares of 10p each

GB00BYV3J755

15,176,204


11.8%












SUBTOTAL 8. A

15,176,204

11.8%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlement xii

Number of voting rights

% of voting rights






















SUBTOTAL 8.B.2




 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii


Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Acacia Research

Corporation

11.8%


11.8%

Merton Acquisition Holdco LLC

11.8%


11.8%






10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional information xvi

Merton Acquisition Holdco LLC is a wholly-owned subsidiary of Acacia Research Corporation.

 

Place of completion

New York, New York, USA

Date of completion

28/09/2020

 

 

-ENDS-

 

 

For more information please contact:

Sensyne Health  (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer


Michael Norris, Chief Financial Officer


 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown


Consilium Strategic Communications

+44 (0) 77 0286 8207

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


[email protected]


 

 

About Sensyne Health  

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAPNNALLEEEA

a d v e r t i s e m e n t